Leprosy

Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis.[1][2] Infection can lead to damage of the nerves, respiratory tract, skin, and eyes.[1] This nerve damage may result in the loss of nociception, which can lead to the loss of parts of a person's extremities from repeated injuries or infection through unnoticed wounds.[3] An infected person may also experience muscle weakness and loss of eyesight.[3] Leprosy symptoms may begin within one year or take 20 years or more.[1]

Leprosy is spread between people, although extensive contact is necessary.[3][4] Leprosy has a low pathogenicity, and 95% of people who contract or who are exposed to M. leprae do not develop the disease.[5] Spread is likely through a cough or contact with fluid from the nose of a person infected by leprosy.[4][5] Genetic factors and baseline immune function play a role in how easily a person catches the disease.[5][6] Leprosy is not spread during pregnancy to the unborn child or through sexual contact.[4] There are two main types of the disease—paucibacillary and multibacillary, which differ in the number of bacteria present.[3] A person with paucibacillary disease has five or fewer poorly pigmented, numb skin patches, while a person with multibacillary disease has more than five skin patches.[3] The diagnosis is confirmed by finding acid-fast bacilli in a biopsy of the skin.[3]

Leprosy is curable with multidrug therapy.[1] Treatment of paucibacillary leprosy is with the medications dapsone, rifampicin, and clofazimine for six months.[5] Treatment for multibacillary leprosy uses the same medications for 12 months.[5] Several other antibiotics may also be used.[3] These treatments are provided free of charge by the World Health Organization.[1]

Leprosy is not highly contagious.[7] People with leprosy can live with their families and attend school and work.[8] In the 1980s, there were 5.2 million cases globally, but by 2020 this decreased to fewer than 200,000.[1][9][10] Most new cases occur in one of 14 countries, with India accounting for more than half of all new cases.[3][1] In the 20 years from 1994 to 2014, 16 million people worldwide were cured of leprosy.[1] Separating people affected by leprosy by placing them in leper colonies is not supported by evidence but still occurs in some areas of India,[11] China,[12] Japan,[13] Africa,[7] and Thailand.[14]

Leprosy has affected humanity for thousands of years.[3] The disease takes its name from the Greek word λέπρα (lépra), from λεπίς (lepís; 'scale'), while the term "Hansen's disease" is named after the Norwegian physician Gerhard Armauer Hansen.[3] Leprosy has historically been associated with social stigma, which continues to be a barrier to self-reporting and early treatment.[1] Leprosy is classified as a neglected tropical disease.[15] World Leprosy Day was started in 1954 to draw awareness to those affected by leprosy.[16][1] The study of leprosy and its treatment is known as leprology.[17]

## Contents

* 1 Signs and symptoms
* 2 Cause
* 2.1 Mycobacterium leprae and M. lepromatosis
* 2.2 Risk factors
* 2.3 Transmission
* 2.4 Genetics
* 3 Pathogenesis
* 3.1 Immunology
* 4 Diagnosis
* 4.1 Classification
* 5 Complications
* 6 Prevention
* 7 Treatment
* 8 Outcomes
* 9 Epidemiology
* 10 History
* 10.1 Historical distribution
* 10.2 Discovery and scientific progress
* 10.3 Treatment
* 10.4 Treatment cost
* 11 Etymology
* 12 Society and culture
* 12.1 Historical texts
* 12.2 Middle Ages
* 12.3 19th century
* 12.4 20th and 21st century
* 12.5 Stigma
* 13 Public policy
* 14 Notable cases
* 15 In media
* 16 Infection of animals
* 17 References
* 18 Further reading
* 19 External links

## Signs and symptoms

Common symptoms present in the different types of leprosy include a rhinorrhea; dry scalp; vision problems; skin lesions; muscle weakness; reddish skin; smooth, shiny, diffuse thickening of facial skin, ear, and hand tissues; loss of sensation in fingers and toes; thickening of peripheral nerves; a flat nose from the destruction of nasal cartilage; and changes in phonation and other aspects of speech production.[18] In addition, atrophy of the testes and erectile dysfunction may occur.[19]

Leprosy onset varies between individuals.[5] The average incubation period is five years, but the infected may begin to notice symptoms within the first year or up to 20 years after infection.[1] Oftentimes, the first noticeable sign of leprosy is the development of pale or pink-coloured patches of skin that may be insensitive to temperature or pain.[20] Patches of discolored skin are sometimes accompanied or preceded by nerve problems, including numbness or tenderness in the hands or feet.[20][21] Secondary infections (bacterial or viral infections consequent to the primary infection) can result in tissue loss, causing fingers and toes to become shortened and deformed as cartilage is absorbed into the body.[22][23] Baseline immune function drives at least some parts of pathogenesis variability.[24]

Approximately 30% of individuals affected by leprosy experience nerve damage.[25] The nerve damage sustained is reversible when treated early, but becomes permanent when appropriate treatment is delayed by several months. Damage to nerves may cause loss of muscle function, leading to paralysis. It may also lead to sensation abnormalities or numbness, leading to additional infections, ulcerations, and joint deformities.[25]

* Face severely deformed by leprosy

Face severely deformed by leprosy

* Hands deformed by leprosy

* Face mildly deformed by leprosy

## Cause

### Mycobacterium leprae and M. lepromatosis

M. leprae, one of the causative agents of leprosy: As an acid-fast bacterium, M. leprae appears red when a Ziehl–Neelsen stain is used

Mycobacterium leprae and Mycobacterium lepromatosis are the mycobacteria that cause leprosy.[25] M. lepromatosis is a relatively newly identified mycobacterium isolated from a fatal case of diffuse lepromatous leprosy in 2008.[26][27] M. lepromatosis is indistinguishable clinically from M. leprae.[28] M. leprae is an aerobic, rod-shaped, acid-fast bacterium with a waxy cell envelope characteristic of the genus Mycobacterium.[29] M. leprae and M. lepromatosis are obligate intracellular pathogens and cannot grow or be cultured outside of host tissues.[26][30] However, they can be grown using research animals such as mice and armadillos.[31][32]

Naturally occurring infections have been reported in nonhuman primates (including the African chimpanzee, the sooty mangabey, and the cynomolgus macaque), armadillos,[33] and red squirrels.[34] Multilocus sequence typing of the armadillo M. leprae strains suggests that they were of human origin for at most a few hundred years.[35] Thus, it is suspected that armadillos first acquired the organism incidentally from early European explorers of the Americas.[36] This incidental transmission was sustained in the armadillo population. It may be transmitted back to humans, making leprosy a zoonotic disease (spread between humans and animals).[36]

Red squirrels (Sciurus vulgaris), a threatened species in Great Britain, were found to carry leprosy in November 2016.[37] It has been suggested that the trade in red squirrel fur, highly prized in the medieval period and intensively traded, may have been responsible for the leprosy epidemic in medieval Europe.[38] A pre-Norman era skull excavated in Hoxne, Suffolk, in 2017 was found to carry DNA from a strain of M. leprae which closely matched the strain carried by modern red squirrels on Brownsea Island.[38][39]

### Risk factors

The greatest risk factor for developing leprosy is contact with another person infected with leprosy.[1] People who are exposed to a person who has leprosy are 5–8 times more likely to develop leprosy than members of the general population.[40] Leprosy occurs more commonly among those living in poverty.[3] Not all people who are infected with M. leprae develop symptoms.[41][42]

Conditions that reduce immune function, such as malnutrition, other illnesses, or genetic mutations, may increase the risk of developing leprosy.[40] Infection with HIV does not appear to increase the risk of developing leprosy.[43] Certain genetic factors in the person exposed have been associated with developing lepromatous or tuberculoid leprosy.[44]

### Transmission

Transmission of leprosy occurs during close contact with those who are infected.[1] Transmission of leprosy is through the upper respiratory tract.[5][45] Older research suggested the skin as the main route of transmission, but research has increasingly favored the respiratory route.[46] Transmission occurs through inhalation of bacilli present in upper airway secretion.[47]

Leprosy is not sexually transmitted and is not spread through pregnancy to the unborn child.[1][4] The majority (95%) of people who are exposed to M. leprae do not develop leprosy; casual contact such as shaking hands and sitting next to someone with leprosy does not lead to transmission.[1][48] People are considered non-infectious 72 hours after starting appropriate multi-drug therapy.[49] Two exit routes of M. leprae from the human body that are often described are the skin and the nasal mucosa, although their relative importance is not clear. Lepromatous cases show large numbers of organisms deep in the dermis, but whether they reach the skin surface in sufficient numbers is doubtful.[50] Humans can acquire a leprosy infection from armadillos by handling them or consuming armadillo meat.[51][52] The mechanism is not fully understood.[4][53][54]

### Genetics

Name  | Locus | OMIM  | Gene

|
|
|

LPRS1  | 10p13  | Online Mendelian Inheritance in Man (OMIM) 609888 |
LPRS2  | 6q25  | Online Mendelian Inheritance in Man (OMIM) 607572 | PARK2, PACRG
LPRS3  | 4q32  | Online Mendelian Inheritance in Man (OMIM) 246300 | TLR2
LPRS4  | 6p21.3  | Online Mendelian Inheritance in Man (OMIM) 610988 | LTA
LPRS5  | 4p14  | Online Mendelian Inheritance in Man (OMIM) 613223 | TLR1
LPRS6  | 13q14.11  | Online Mendelian Inheritance in Man (OMIM) 613407 |

Not all people infected or exposed to M. leprae develop leprosy, and genetic factors are suspected to play a role in susceptibility to an infection.[55] Cases of leprosy often cluster in families, and several genetic variants have been identified.[55] In many who are exposed, the immune system can eliminate the leprosy bacteria during the early infection stage before severe symptoms develop.[56] A genetic defect in cell-mediated immunity may cause a person to be susceptible to develop leprosy symptoms after exposure to the bacteria.[57] The region of DNA responsible for this variability is also involved in Parkinson's disease, giving rise to current speculation that the two disorders may be linked at the biochemical level.[57]

## Pathogenesis

Most leprosy complications are the result of nerve damage. The nerve damage occurs due to direct invasion by the M. leprae bacteria and a person's immune response, resulting in inflammation.[25] The molecular mechanism underlying how M. leprae produces the symptoms of leprosy is not clear,[10] but M. leprae has been shown to bind to Schwann cells, which may lead to nerve injury including demyelination and a loss of nerve function (specifically a loss of axonal conductance).[58] Numerous molecular mechanisms have been associated with this nerve damage including the presence of a laminin-binding protein and the glycoconjugate (PGL-1) on the surface of M. leprae that can bind to laminin on peripheral nerves.[58]

As part of the human immune response, white blood cell-derived macrophages may engulf M. leprae by phagocytosis.[58] In the initial stages, small sensory and autonomic nerve fibers in the skin of a person with leprosy are damaged.[25] This damage usually results in hair loss to the area, a loss of the ability to sweat, and numbness (decreased ability to detect sensations such as temperature and touch). Further peripheral nerve damage may result in skin dryness, more numbness, and muscle weakness or paralysis in the affected area.[25] The skin can crack, and if the skin injuries are not carefully cared for, there is a risk for a secondary infection that can lead to more severe damage.[25]

### Immunology

Leprosy exhibits polarized host responses along a Th1–Th2 spectrum that underpins the Ridley–Jopling clinicopathological forms. At the tuberculoid pole (TT/BT), cellular immunity is dominated by Th1 cytokines—notably IL-12, IFN-γ and TNF-α—which activate macrophages, favor granuloma organization, and restrict bacillary multiplication; at the lepromatous pole (BL/LL), there is Th2/regulatory bias (e.g., IL-4, IL-10), weaker cell-mediated immunity, and high bacillary loads with widespread dissemination.[59] This polarization is shaped by antigen-presenting cell function and pattern-recognition events: recognition of mycobacterial ligands by Toll-like receptors—particularly TLR1/2 heterodimers on macrophages, dendritic cells, and Schwann cells—drives Th1-skewing in paucibacillary disease, whereas IL-10-rich regulatory circuits dampen effector responses at the multibacillary pole.[59]

Histopathology reflects these immune states. Tuberculoid lesions show well-formed granulomas composed of epithelioid macrophages and multinucleated giant cells with dense T-cell cuffs, consistent with attempts at bacillary containment; bacilli are scant and often absent on routine sections. By contrast, lepromatous lesions display diffuse sheets of vacuolated "foamy" macrophages packed with bacilli (including globi), fewer cytotoxic effectors, and more permissive tissue microenvironments.[60] Macrophage programs diverge across the spectrum: microbicidal, nitric-oxide–producing phenotypes are more characteristic of the Th1 side, whereas alternative (M2-like), lipid-rich programs prevail at the Th2/regulatory pole.[59]

Additional T-cell axes contribute to bacterial control and tissue damage: Th17/IL-17 responses, typically higher in tuberculoid disease, align with granulomatous inflammation, while FoxP3+ T-regulatory cells and TGF-β/IL-10 pathways are more prominent in multibacillary disease and can suppress protective immunity.[59][60] Superimposed acute "reactions" represent abrupt shifts on this immunologic continuum. Type 1 (reversal) reactions, usually in borderline disease, involve amplification of Th1-driven inflammation with edema of pre-existing lesions and neuritis. Type 2 reactions (erythema nodosum leprosum) are systemic inflammatory episodes linked to high antigen load and immune-complex formation, with fever, tender nodules, neutrophilia, and other organ involvement; their pathobiology features surges of TNF-α, IL-6, and IL-8 and neutrophil-rich infiltrates.[60][59]

Beyond T cells and macrophages, humoral immunity and B-cell subsets are also implicated. B-1–like cells (by PAX5/CD5 labeling) and marginal zone B cells in human cutaneous lesions—together with Be1 cells—were more abundant in tuberculoid and type 1 reaction lesions than in lepromatous, type 2 reaction, and indeterminate forms, consistent with Th1-skewed inflammation; IL-10–producing regulatory B cells were infrequent.[61] These findings expand the repertoire of cellular players involved at the paucibacillary/Th1 pole of the leprosy spectrum.[61]

## Diagnosis

Testing for loss of sensation with monofilament

In countries where people are frequently infected, a person is considered to have leprosy if they have one of the following two signs:

* Skin lesion consistent with leprosy and with definite sensory loss.[1]
* Positive skin smears.[1]

Skin lesions can be single or multiple, usually hypopigmented, although occasionally reddish or copper-colored.[1] The lesions may be flat (macules), raised (papules), or solid elevated areas (nodular).[1] Experiencing sensory loss at the skin lesion is a feature that can help determine if the lesion is caused by leprosy or by another disorder such as tinea versicolor.[1][62] Thickened nerves are associated with leprosy and can be accompanied by loss of sensation or muscle weakness, but muscle weakness without the characteristic skin lesion and sensory loss is not considered a reliable sign of leprosy.[1] In some cases, the presence of acid-fast leprosy bacilli in skin smears is considered diagnostic; however, the diagnosis is typically made without laboratory tests, based on symptoms.[1] If a person has a new leprosy diagnosis and already has a visible disability caused by leprosy, the diagnosis is considered late.[25]

In countries or areas where leprosy is uncommon, such as the United States, diagnosis of leprosy is often delayed because healthcare providers are unaware of leprosy and its symptoms.[63] Early diagnosis and treatment prevent nerve involvement, the hallmark of leprosy, and the disability it causes.[1][63] There is no recommended test to diagnose latent leprosy in people without symptoms.[5] Few people with latent leprosy test positive for anti PGL-1.[41] The presence of M. leprae bacterial DNA can be identified using a polymerase chain reaction (PCR)-based technique.[64] This molecular test alone is not sufficient to diagnose a person, but this approach may be used to identify someone who is at high risk of developing or transmitting leprosy such as those with few lesions or an atypical clinical presentation.[64][65] New approaches propose tools to diagnose leprosy through artificial intelligence.[66]

### Classification

Several approaches for classifying leprosy exist. There are similarities between the classification approaches.

* The World Health Organization (WHO) system distinguishes patients with five or fewer skin lesions and no bacilli in a skin smear as "paucibacillary" ("pauci-" refers to a small quantity) from patients with more lesions or detected bacilli as "multibacillary".[67]
* The Ridley-Jopling scale provides five gradations.[68][69][70]
* The ICD-10, though developed by the WHO, uses Ridley-Jopling, not the WHO system. It also adds an indeterminate ("I") entry.[50]
* In MeSH, three groupings are used.

WHO  | Ridley-Jopling  | ICD-10 | MeSH | Description  | Lepromin test

|
|
|
|
|

Paucibacillary  | tuberculoid ("TT"),
borderline
tuberculoid ("BT")  | A30.1, A30.2  | Tuberculoid  | It is characterized by one or more hypopigmented skin macules and patches where skin sensations are lost because of damaged peripheral nerves that have been attacked by the human host's immune cells. TT is characterized by the formation of epithelioid cell granulomas with a large number of epithelioid cells. In this form of leprosy, Mycobacterium leprae is either absent from the lesion or occurs in very small numbers. This type of leprosy is most benign.[58][71] | Positive
Multibacillary  | midborderline

borderline ("BB")  | A30.3  | Borderline  | Negative
Multibacillary  | borderline lepromatous ("BL"),
and lepromatous ("LL")  | A30.4, A30.5  | Lepromatous  | It is associated with symmetric skin lesions, nodules, plaques, thickened dermis, and frequent involvement of the nasal mucosa resulting in nasal congestion and nose bleeds, but, typically, detectable nerve damage is late. Loss of eyebrows and lashes can be seen in advanced disease.[72] LL is characterized by the absence of epithelioid cells in the lesions. In this form of leprosy, Mycobacteria leprae are found in lesions in large numbers. This is the most unfavorable clinical variant of leprosy, which occurs with a generalized lesion of the skin, mucous membranes, eyes, peripheral nerves, lymph nodes, and internal organs.[58][71] Histoid leprosy is a rare variation of multibacillary, lepromatous leprosy.  | Negative

Leprosy may also occur with only neural involvement, without skin lesions.[1][73][74][75][76][77]

## Complications

Leprosy causes tissue loss and deformity by attacking nerve endings, leading to loss of sensation and increased injury risk. Injuries can become infected, causing tissue damage and shortening of fingers, toes, and limbs.[78]

## Prevention

File:Leprosy; patients showing symptoms. Wellcome L0077162.jpgLeprosy prevention poster

Early disease detection is important, since physical and neurological damage may be irreversible even if cured.[1] Medications can decrease the risk of those living with people who have leprosy from acquiring the disease, and likely those with whom people with leprosy come into contact outside the home.[10] The WHO recommends that preventive medicine be given to people who are in close contact with someone who has leprosy.[5] The suggested preventive treatment is a single dose of rifampicin in adults and children over 2 years old who do not already have leprosy or tuberculosis.[5] Preventive treatment is associated with a 57% reduction in infections within 2 years and a 30% reduction in infections within 6 years.[5]

The Bacillus Calmette–Guérin (BCG) vaccine offers a variable amount of protection against leprosy in addition to its closely related target of tuberculosis.[79] It appears to be 26% to 41% effective (based on controlled trials) and about 60% effective based on observational studies, with two doses possibly working better than one.[80][81] The WHO concluded in 2018 that the BCG vaccine at birth reduces leprosy risk and is recommended in countries with high incidence of TB and people who have leprosy.[82] People living in the same home as a person with leprosy are suggested to take a BCG booster which may improve their immunity by 56%.[83][84] Development of a more effective vaccine is ongoing.[10][85][86][87]

A novel vaccine called LepVax entered clinical trials in 2017 with the first encouraging results reported on 24 participants published in 2020.[88][89] If successful, this would be the first leprosy-specific vaccine available.

## Treatment

File:Municipality of Culion outlook from local hillside.jpgCulion leper colony in Culion old town in Palawan, Philippines, used to shelter one of the largest population of lepers in Asia, numbering between 3,500 and 4,000 in the early 1900s.[90][91] MDT antileprosy drugs: standard regimens from 2010

Several leprostatic agents are available for treatment. A three-drug regimen of rifampicin, dapsone, and clofazimine is recommended for all people with leprosy, for six months for paucibacillary leprosy and 12 months for multibacillary leprosy.[5] Multidrug therapy (MDT) remains highly effective, and people are no longer infectious after the first monthly dose.[1] MDT is safe and easy to use under field conditions because it is available in calendar-labelled blister packs.[1] The treatment does pose compliance challenges for young children who find swallowing multiple solid pills difficult.[92] Post-treatment relapse rates remain low.[1]

The combination treatment accelerates treatment and decreases the chance of creating drug-resistant bacteria. All three drugs in the three-drug regimen are antibacterial, with rifampicin being the most potent. Rifampicin is scheduled monthly since it interferes with dapsone by inducing its increased metabolism.[93]

Resistance to the three-drug regimen has been reported in several countries, although the number of cases is small.[94] People with rifampicin-resistant leprosy may be treated with second-line medications such as fluoroquinolones, minocycline, or clarithromycin, but the treatment duration is 24 months because of their lower bactericidal activity.[95] Evidence on the potential benefits and harms of alternative regimens for drug-resistant leprosy is not available.[5]

For people with nerve damage, protective footwear may help prevent ulcers and secondary infections.[25] Canvas shoes may be better than PVC boots.[25] There may be no difference between double rocker shoes and below-knee plaster.[25] Topical ketanserin seems to have a better effect on ulcer healing than clioquinol cream or zinc paste, but the evidence for this is weak.[25] Phenytoin applied to the skin improves skin changes to a greater degree when compared to saline dressings.[25]

## Outcomes

Although leprosy has been curable since the mid-20th century, left untreated, it can cause permanent physical impairments and damage to a person's nerves, skin, eyes, and limbs.[1] Despite leprosy not being very infectious and having a low pathogenicity, there is still significant stigma and prejudice associated with the disease.[96] Because of this stigma, leprosy can affect a person's participation in social activities and may also affect the lives of their family and friends.[96] People with leprosy are also at a higher risk for problems with their mental well-being.[96] The social stigma may contribute to problems obtaining employment, financial difficulties, and social isolation.[96] Efforts to reduce discrimination and reduce the stigma surrounding leprosy may help improve outcomes for people with leprosy.[97]

## Epidemiology

Main article: Medicine:Epidemiology of leprosy

Template:Owidslider In 2018, 208,619 new cases of leprosy were recorded, a slight decrease from 2017.[98] In 2015, 94% of the new leprosy cases were confined to 14 countries.[99] India reported the greatest number of new cases (60% of reported cases), followed by Brazil (13%) and Indonesia (8%).[99] Although the number of cases worldwide continues to fall, there are parts of the world where leprosy is more common, including Brazil, South Asia (India, Nepal, Bhutan), some parts of Africa (Tanzania, Madagascar, Mozambique), and the western Pacific.[99] About 150 to 250 cases are diagnosed in the United States each year.[100]

In the 1960s, there were tens of millions of leprosy cases recorded when the bacteria started to develop resistance to dapsone, the most common treatment option at the time.[1][10] International (e.g., the WHO's "Global Strategy for Reducing Disease Burden Due to Leprosy" and the International Federation of Anti-Leprosy Associations) and national initiatives have reduced the total number and the number of new cases of the disease.[10][101]

The number of new leprosy cases is difficult to measure and monitor because of leprosy's long incubation period, delays in diagnosis after the onset of the disease, and lack of medical care in affected areas.[102] The registered prevalence of the disease is used to determine disease burden.[103] Registered prevalence is a useful proxy indicator of the disease burden, as it reflects the number of active leprosy cases diagnosed with the disease and receiving treatment with MDT at a given point in time.[103] The prevalence rate is defined as the number of cases registered for MDT treatment among the population in which the cases have occurred, again at a given point in time.[103]

Year  | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | 2014  | 2015  | 2016  | 2017  | 2018  | 2019  | 2020  | 2021  | 2022  | 2023  | 2024

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

No. of new cases[104] | 296,479  | 258,980  | 252,541  | 249,018  | 244,797  | 228,488  | 224,344  | 232,847  | 215,636  | 213,861  | 211,945  | 217,927  | 210,973  | 208,613  | 202,166  | 127,506  | 140,546  | 174,059  | 182,792  | 215,636

## History

Norwegian physician Gerhard Armauer Hansen (1841–1912) discovered M. leprae in 1873.

### Historical distribution

Using comparative genomics, in 2005, geneticists traced the origins and worldwide distribution of leprosy from East Africa or the Near East along human migration routes. They found four strains of M. leprae with specific regional locations:[105] Monot et al. (2005) determined that leprosy originated in East Africa or the Near East and traveled with humans along their migration routes, including those of trade in goods and slaves. The four strains of M. leprae are based in specific geographic regions where each predominantly occurs:[105]

* strain 1 in Asia, the Pacific region, and East Africa;
* strain 2 in Ethiopia, Malawi, Nepal, north India, and New Caledonia;
* strain 3 in Europe, North Africa, and the Americas;
* strain 4 in West Africa and the Caribbean.

This confirms the spread of the disease along the migration, colonisation, and slave trade routes taken from East Africa to India, West Africa to the New World, and from Africa to Europe and vice versa.[106]

Skeletal remains discovered in 2009 represent the oldest documented evidence for leprosy, dating to the 2nd millennium BC.[107][108] Located at Balathal, Rajasthan, in northwest India, the discoverers suggest that if the disease did migrate from Africa to India during the 3rd millennium BC "at a time when there was substantial interaction among the Indus Civilization, Mesopotamia, and Egypt, there needs to be additional skeletal and molecular evidence of leprosy in India and Africa to confirm the African origin of the disease".[109] A proven human case was verified by DNA taken from the shrouded remains of a man discovered by researchers from the Hebrew University of Jerusalem in a tomb in Akeldama, next to the Old City of Jerusalem dated by radiocarbon methods to the first half of the 1st century.[110]

The oldest strains of leprosy known from Europe are from Great Chesterford in southeast England and date back to AD 415-545\. These findings suggest a different path for the spread of leprosy, meaning it may have originated in Western Eurasia. This study also indicates that there were more strains in Europe at the time than previously determined.[111]

### Discovery and scientific progress

Distribution of leprosy around the world in 1891

Literary attestation of leprosy is unclear because of the ambiguity of many early sources, including the Indian Atharvaveda and Kausika Sutra, the Egyptian Ebers Papyrus, and the Hebrew Bible's various sections regarding signs of impurity (tzaraath).[112] Leprotic symptoms are attested in the Indian doctor Sushruta's Compendium, originally dating to c. 600 BC but only surviving in emended texts no earlier than the fifth century BC. Symptoms consistent with leprosy were possibly described by Hippocrates in 460 BC.[113] However, Hansen's disease probably did not exist in Greece or the Middle East before the Common Era.[114][115][116] In 1846, Francis Adams produced The Seven Books of Paulus Aegineta which included a commentary on all medical and surgical knowledge and descriptions and remedies to do with leprosy from the Romans, Greeks, and Arabs.[117]

The first known causative agent of leprosy, M. leprae, was discovered by Gerhard Armauer Hansen in Norway in 1873, making it one of the first species of pathogenic bacteria to be identified.[118] Leprosy was once believed to have been absent from the Americas before the age of Discovery and the arrival of Europeans.[119] In 2008, a different causative agent for leprosy, Mycobacterium lepromatosis was discovered. DNA studies have revealed that this pathogen exists primarily in the Americas and was already present before Europeans arrived.[120] It is believed that it did not exist in Polynesia until the middle of the 19th century.[121]

### Treatment

Chaulmoogra tree oil was used topically to manage Hansen's disease for centuries. Chaulmoogra oil could not be taken orally without causing nausea or injected without forming an abscess.[122] Leprosy was once believed to be highly contagious and was treated with mercury, as was syphilis, which was first described in 1530. Many early cases thought to be leprosy could actually have been syphilis.[123] In 1915, Alice Ball, the first black woman to graduate from the University of Hawaiʻi with a master's in chemistry, discovered how to make the oil water-soluble.[122] This technique led to marked improvements in patients with Hansen's disease who were treated in Hawaii.[122]

The first effective drug (promin) became available in the 1940s.[124] In the 1950s, dapsone was introduced. The search for further effective antileprosy drugs led to the use of clofazimine and rifampicin in the 1960s and 1970s.[125] Later, Indian scientist Shantaram Yawalkar and his colleagues formulated a combined therapy using rifampicin and dapsone, intended to mitigate bacterial resistance.[126] Combining all three drugs was first recommended by the WHO in 1981. These three drugs are still used in the standard MDT regimens.[127] Resistance has developed to initial treatment. Until the introduction of MDT in the early 1980s, leprosy could not be diagnosed and treated successfully within the community.[128]

The importance of the nasal mucosa in the transmission of M. leprae was recognized as early as 1898 by Schäffer, particularly the ulcerated mucosa.[129] The mechanism of plantar ulceration in leprosy and its treatment was first described by Ernest W. Price.[130]

### Treatment cost

Between 1995 and 1999, the WHO, with the aid of the Nippon Foundation, supplied all endemic countries with free MDT in blister packs, channeled through ministries of health.[1] This free provision was extended in 2000 and again in 2005, 2010, and 2015 with donations by the MDT manufacturer Novartis through the WHO.[131][1] At the national level, non-governmental organizations (NGOs) affiliated with the national program will continue to be provided with an appropriate free supply.[132]

## Etymology

## Society and culture

Two lepers denied entrance to town, 14th century

### Historical texts

Written accounts of leprosy date back thousands of years. By 600 BC, various skin diseases translated as leprosy appear in the Atharva Veda, a principal Hindu scripture.[133] Another Hindu scripture, the Manusmriti (200 BC), prohibits contact with those infected with the disease and makes marriage to a person infected with leprosy punishable.[134]

The Hebraic root tsara or tsaraath (צָרַע, – tsaw-rah' – to be struck with leprosy, to be leprous) and the Greek (λεπρός – lepros), are of broader classification than the more narrow use of the term related to Hansen's Disease.[135] Any progressive skin disease (a whitening or splotchy bleaching of the skin, raised manifestations of scales, scabs, infections, rashes, etc.) — as well as generalized molds and surface discoloration of any clothing, leather, or discoloration on walls or surfaces throughout homes — all came under the "law of leprosy" (Leviticus 14:54–57).[136] Ancient sources such as the Talmud (Sifra 63) make clear that tzaraath refers to various types of lesions or stains associated with ritual impurity and occurring on cloth, leather, or houses, as well as skin. Traditional Judaism and Jewish rabbinical authorities, both historical and modern, emphasize that the tsaraath of Leviticus is a spiritual ailment with no direct relationship to Hansen's disease or physical contagions. The relation of tsaraath to "leprosy" comes from translations of Hebrew Biblical texts into Greek and ensuing misconceptions.[137]

All three Synoptic Gospels of the New Testament describe instances of Jesus healing people with leprosy (Matthew 8:1–4, Mark 1:40–45, and Luke 5:12–16). The Bible's description of leprosy is congruous (if lacking detail) with the symptoms of modern leprosy, but the relationship between this disease, tzaraath, and Hansen's disease has been disputed.[138] The biblical perception that people with leprosy were unclean can be found in a passage from Leviticus 13:44–46. While this text defines the leper as impure, it does not explicitly make a moral judgement on those with leprosy.[139] Some early Christians believed that God was punishing those affected by leprosy for sinful behavior. Moral associations have persisted throughout history. In the 6th century, Pope Gregory the Great and Isidore of Seville considered people with the disease to be heretics.[140]

### Middle Ages

Medieval leper bell

The general population's perception of leprosy was mixed. On one hand, people feared getting infected with the disease and thought of people suspected of leprosy to be unclean, untrustworthy, and occasionally morally corrupt.[140] On the other hand, Jesus' interaction with lepers, the writing of church leaders, and the Christian focus on charitable works led to viewing the lepers as "chosen by God"[141] or seeing the disease as a means of obtaining access to heaven.[142]

Early medieval understanding of leprosy was influenced by early Christian writers such as Gregory of Nazianzus and John Chrysostom, whose writings were later embraced by Byzantine and Latin writers.[143] Gregory, for example, composed sermons urging Christians to assist victims of the disease, and he condemned pagans or Christians who justified rejecting lepers on the allegation that God had sent them the disease to punish them. As cases of leprosy increased in the Eastern Roman Empire, becoming a major health issue, the ecclesiastic leaders discussed how to assist those affected as well as how to change the attitude of society towards them. They also tried this by using the name "holy disease" instead of the commonly used "elephant's disease" (elephantiasis), implying that God did not create this disease to punish people but to purify them for heaven.[144] Although not always successful in persuading the public and a cure was never found by Greek medicians, they created an environment where victims could get palliative care and were never expressly banned from society, as sometimes happened in western Europe. Theodore Balsamon, a 12th-century jurist in Constantinople, noted that lepers were allowed to enter the same churches, cities, and assemblies that healthy people attended.[143]

As the disease became more prevalent in Western Europe in the fifth century, efforts began to establish permanent institutions to house and feed lepers. These efforts were, inclusively, the work of bishops in France at the end of the sixth century, such as in Chalon-sur-Saône.[143] The increase in hospitals or leprosaria (sing. leprosarium) that treated people with leprosy in the 12th and 13th centuries seems to indicate a rise in cases,[145][146][147] possibly in connection with the increase in urbanisation[148] as well as returning crusaders from the Middle East.[143] France alone had nearly 2,000 leprosaria during this period.[149] Additionally to the new leprosia, further steps were taken by secular and religious leaders to prevent further spread of the disease. The third Lateran Council of 1179 required lepers to have their own priests and churches[148] and a 1346 edict by King Edward expelled lepers from city limits. Segregation from mainstream society became common, and people with leprosy were often required to wear clothing that identified them as such or carry a bell announcing their presence.[149] As in the East, it was the Church who took care of the lepers due to the persisting moral stigma and who ran the leprosaria.[140][150] Although the leprosaria in Western Europe removed the sick from society, they were never a place to quarantine them or from which they could not leave: lepers would go beg for alms for the upkeep of the leprosaria or meet with their families.[148][143]

Multiple groups in Western Europe from the Middle Ages faced social ostracization and discrimination that was justified, in part, due to claims that they were the descendants of lepers. These groups included the Cagots and the Caquins.[151][152][153]

### 19th century

A 24-year-old man with leprosy, 1886

Norway was the location of a progressive stance on leprosy tracking and treatment, and played an influential role in European understanding of the disease. In 1832, Dr. JJ Hjort conducted the first leprosy survey, thus establishing a basis for epidemiological surveys. Subsequent surveys led to the establishment of a national leprosy registry to study the causes of leprosy and to track the rate of infection. Early leprosy research throughout Europe was conducted by Norwegian scientists Daniel Cornelius Danielssen and Carl Wilhelm Boeck. Their work resulted in the establishment of the National Leprosy Research and Treatment Center. Danielssen and Boeck believed the cause of leprosy transmission was hereditary. This stance was influential in advocating for the isolation of those infected by sex to prevent reproduction.[154][155][156]

File:Mary Glowrey (1887-1957) with a patient with leprosy in Guntur, India circa 1926.webpMary Glowrey (1887–1957) with a patient with leprosy in Guntur, India circa 1926

Though leprosy rates were on the decline in the Western world by the 1860s, authorities frequently embraced isolation treatment due to a combination of reasons, including fears of the disease spreading from the Global South, efforts by Christian missionaries and a lack of understanding concerning bacteriology, medical diagnosis and how contagious the disease was.[157] The rapid expansion of Western imperialism during the Victorian era resulted in westerners coming into increasing contact with regions where the disease was endemic, including British India. English surgeon Henry Vandyke Carter observed isolation treatment for leprosy patients first-hand while visiting Norway, applying these methods in British India with the financial and logistical assistance of Protestant missionaries. Colonialist and religious viewpoints of the disease continued to be a major factor in the treatment and public perception of the disease in the Global South until decolonization in the mid-20th century.[157]

### 20th and 21st century

In 1898, the colonial government in British India enacted the Leprosy Act of 1898, which mandated the compulsory segregation of people with leprosy by authorities in newly established leper asylums, where they were segregated by sex to prevent sexual activity. The act, which proved difficult to enforce, was repealed in 1983 by the Indian government after MDT had become widely available in India. In 1983, the National Leprosy Elimination Programme, previously the National Leprosy Control Programme, changed its methods from surveillance to the treatment of people with leprosy. India still accounts for over half of the global disease burden. According to the WHO, new cases in India during 2019 diminished to 114,451 patients (57% of the world's total new cases).[158][157] Until 2019, Indians could justify a petition for divorce with their spouse's diagnosis of leprosy.[159]

The National Leprosarium at Carville, Louisiana, known in 1955 as the Louisiana Leper Home, was the only leprosy hospital in the mainland United States. Leprosy patients from all over the United States were sent to Carville to be kept in isolation away from the public, as not much about leprosy transmission was known at the time, and stigma against those with leprosy was high. The Carville leprosarium was known for its innovations in reconstructive surgery for those with leprosy. In 1941, 22 patients at Carville underwent trials for a new drug called Promin. The results were described as miraculous, and soon after the success of promin came dapsone, a medicine even more effective in the fight against leprosy.[160] Leprosy incidence peaked in the United States in 1983, followed by a steep decline.[161] However, case numbers have been slowly rising again since 2000. In 2020, 159 cases were reported in the country.[161]

### Stigma

See also: Leprosy stigma and Leper colony stigma

Depictions of a 26-year-old woman with leprous lesions and a 13-year-old boy with severe leprosy in Daniel Cornelius' 1847 Om Spedalskhed

Despite effective treatment and education efforts, leprosy stigma remains problematic in developing countries where the disease is common. Leprosy is most common amongst impoverished populations where social stigma is likely to be compounded by poverty. Fears of ostracism, job loss, or expulsion from family and society may contribute to a delayed diagnosis and treatment.[162]

Folk beliefs, lack of education, and religious connotations of the disease continue to influence social perceptions of those affected in many parts of the world. In Brazil, for example, folklore holds that leprosy is a disease transmitted by dogs, or that it is associated with sexual promiscuity, or that it is a punishment for sins or moral transgressions (distinct from other diseases and misfortunes, which are in general thought of as being according to the will of God).[163] Socioeconomic factors also have a direct impact. Lower-class domestic workers who are often employed by those in a higher socioeconomic class may find their employment in jeopardy as physical manifestations of the disease become apparent. Skin discoloration and darker pigmentation resulting from the disease also have social repercussions.[164]

In extreme cases in northern India, leprosy is equated with an "untouchable" status that "often persists long after individuals with leprosy have been cured of the disease, creating lifelong prospects of divorce, eviction, loss of employment, and ostracism from family and social networks."[165]

## Public policy

The World Health Organization maintains an Expert Committee on Leprosy since 1954, and a goal of the WHO is to "eliminate leprosy." In 2016 the organization launched "Global Leprosy Strategy 2016–2020: Accelerating towards a leprosy-free world".[166][167] Elimination of leprosy is defined as "reducing the proportion of (people with) leprosy in the community to very low levels, specifically to below one case per 10,000 population".[168] Diagnosis and treatment with multidrug therapy are effective, and a 45% decline in disease burden has occurred since MDT has become more widely available.[169] The organization emphasizes the importance of fully integrating leprosy treatment into public health services, effective diagnosis and treatment, and access to information.[169] The approach includes supporting an increase in health care professionals who understand the disease, and a coordinated and renewed political commitment that includes coordination between countries and improvements in the methodology for collecting and analysing data.[166]

Interventions include:[166]

* Early detection of cases focusing on children to reduce transmission and disabilities.
* Enhanced healthcare services and improved access for people who may be marginalized.
* For countries where leprosy is endemic, further interventions include improved screening of close contacts, improved treatment regimens, and interventions to reduce stigma and discrimination against people who have leprosy.

In some instances in India, community-based rehabilitation is embraced by local governments and NGOs alike. Often, the identity cultivated by a community environment is preferable to reintegration, and models of self-management and collective agency independent of NGOs and government support have been desirable and successful.[170]

## Notable cases

Father Damien on his deathbed on 14 April 1889

* Baldwin IV of Jerusalem (1161–1185), Catholic king of Latin Jerusalem, also known as the "Leper King".[171]
* Henry IV of England (r. 1399–1413) possibly had leprosy.[172]
* Ōtani Yoshitsugu (1558 or 1565–1600), a Japanese daimyō (feudal lord).[173]
* Ingeborg Grytten (c. 1668 – after 1705), Norwegian writer whose leprosy is thought to have influenced her poetry, which is characterized by a strong religious faith in God's salvation.[174]
* Saint Damien De Veuster (1840–1889), a Catholic priest from Belgium, contracted leprosy and ministered to lepers who had been placed under a government-sanctioned medical quarantine on Molokaʻi in the Kingdom of Hawaiʻi.[175]
* Josephine Cafrine of Seychelles (1877–1907) had leprosy from age 12 and kept a journal that documented her struggles and suffering.[176][177][178] It was published as an autobiography in 1923.[176][177][178][179]
* British writer Peter Greave (1910–1977)
* Vietnamese poet Hàn Mặc Tử (1912–1940)[180]
* Josefina Guerrero (1917–1996), Filipino World War II spy who used the Japanese fear of her leprosy to listen to their battle plans and deliver the information to the American forces under Douglas MacArthur.[181]
* Hilarion Guia (1942–2016), Filipino educator who became the first mayor of Culion, Palawan which hosted the Culion leper colony.[182]
* Dimple Kapadia (1957–present), Indian actress, was diagnosed with leprosy a few months before the shoot of the 1973 musical romance film Bobby. She later recovered completely and went on to have a successful acting career.[183]

## In media

* August 1891 — the short story collection Life's Handicap by Rudyard Kipling has a story "The Mark of the Beast" in which a traveller on horseback literally stumbles into a leper colony in India.[184]
* 1909 — Jack London published "Koolau the Leper" in his Tales of Hawaiʻi about Molokai and people consigned to it circa 1893.
* 1959 — James Michener's novel Hawaii dramatizes Molokai's leper settlement, including Father Damien.
* 1959 — Ben-Hur depicts the title character's mother, Miriam, and younger sister, Tirzah, are imprisoned by the Roman Empire. When they are freed years later, they have leprosy and leave town for the Valley of the Lepers, rather than stay and reunite with Ben-Hur. They leave the colony, and when Jesus dies on the cross, they are miraculously cured.
* 1960 — English author Graham Greene's novel A Burnt-Out Case is set in a leper colony in Belgian Congo. The story is also predominantly about a disillusioned architect working with a doctor on devising new cures and amenities for mutilated victims of lepers; the title, too, refers to the condition of mutilation and disfigurement in the disease.[185]
* 1962 — Forugh Farrokhzad made a 22-minute documentary about a leprosy colony in Iran titled The House Is Black. The film humanizes the people affected and opens by saying that "there is no shortage of ugliness in the world, but by closing our eyes on ugliness, we will intensify it."
* 1977 — The lead character in The Chronicles of Thomas Covenant by Stephen R. Donaldson suffers from leprosy. His condition seems to be cured by the magic of the fantasy land he finds himself in. He resists believing in its reality, for example, by continuing to perform a regular visual surveillance of extremities as a safety check. Donaldson gained experience with the disease as a young man in India, where his father worked in a missionary for people with leprosy.
* 1988 — The death metal band Death releases their second album titled Leprosy, with a song also titled "Leprosy", the lyrics of which talk about the progressive decay the disease causes, and the social isolation placed upon people infected.
* 2006 — Moloka'i is a novel by Alan Brennert about a leper colony in Hawaii. This novel follows the story of a seven-year-old girl taken from her family and put on Molokai's leper settlement.
* 2009 — Squint: My Journey with Leprosy is a memoir by Jose P. Ramirez.[186]

## Infection of animals

Between 15 and 20% of nine-banded armadillos (Dasypus novemcinctus) in the south-central United States carry M. leprae.[187][188] As a result of their low body temperature, their tissues commonly contain massive numbers of organisms, which help in the dissemination of the infection. Armadillos were first demonstrated in 1971 to develop leprosy after inoculation with M. leprae.[189] Because of armadillos' armor, skin lesions are difficult to ascertain.[190] Abrasions around the eyes, nose, and feet are the most common signs. Infected armadillos make up a large reservoir of M. leprae. They may be a source of infection for some humans in the United States or other locations in the armadillos' home range. In armadillo leprosy, lesions do not persist at the site of entry in animals; M. leprae multiply in macrophages at the site of inoculation and lymph nodes.[191]

Armadillos have been used in immunological research to fight leprosy. Some notable reagents include recombinant interleukin-2 and recombinant interferon-gamma reagents.[189] Additionally, they have been key and have been useful models of leprosy for studies regarding neuropathy.[192] In clinical procedures such as electrophysiological nerve conduction tests Armadillo's nerve function has been properly assessed.[192] Despite the studies mentioned regarding Armadillo's relationship to neuropathy and other effects of leprosy, there is still a lack of proper study on armadillos, and in conducting more armadillo-specific regents, our understanding of leprosy's effects on armadillos and possible humans can be found. Armadillos are a key component of modern-day research on leprosy.

There is a stigma surrounding armadillos and the carrying of leprosy. Because many people do not understand armadillos very well, it is common for people to think of them as being dangerous to society and, as a result, valuing their lives less than other animals. It has become more common in parts of America for people to eat raw or undercooked armadillo, making the chances high that, if not properly handled with care, one may become infected.[193]

An outbreak in chimpanzees in West Africa showed that the bacteria can infect another species and may have additional rodent hosts.[194] Studies have demonstrated that the disease is endemic in the UK red Eurasian squirrel population, with M. leprae and M. lepromatosis appearing in different populations. The M. leprae strain discovered on Brownsea Island is equated to one thought to have died out in the human population in medieval times.[195] Despite this, and speculation regarding past transmission through trade in squirrel furs, there does not seem to be a high risk of squirrel to human transmission from the wild population. Although leprosy continues to be diagnosed in immigrants to the UK, the last known human case of leprosy arising in the UK was recorded over 200 years ago.[196]

It has been shown that leprosy can reprogram cells in mouse[197][198] and armadillo[199][200] models, similar to how induced pluripotent stem cells are generated by the transcription factors Myc, Oct3/4, Sox2, and Klf4. A notable study conducted by Charles Shepard used mice to find how leprosy, an infection that has a preference for cooler areas of the body, would work in a warm-blooded animal. The main findings were that even in mice whose immune systems were severely impaired and at a perceived high risk of developing leprosy, the body was still, in most cases, able to fight off leprosy. There are a few other up-and-coming models for M. leprae, including the use of other animals, such as mammals, birds, and cold-blooded animals.[189] These animals do not tend to give as great results as armadillos and mice, as different animals have different levels of disease resistance.

## References

1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 Cite error: Invalid `<ref>` tag; no text was provided for refs named `WHO Fact Sheet`
2. ↑ "Two Cases of Leprosy in Siblings Caused by Mycobacterium lepromatosis and Review of the Literature". The American Journal of Tropical Medicine and Hygiene 95 (3): 522–527. September 2016. doi:10.4269/ajtmh.16-0076. PMID 27402522.
3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 "Current status of leprosy: epidemiology, basic science and clinical perspectives". The Journal of Dermatology 39 (2): 121–129. February 2012. doi:10.1111/j.1346-8138.2011.01370.x. PMID 21973237.
4. ↑ 4.0 4.1 4.2 4.3 4.4 "Hansen's Disease (Leprosy) Transmission". 29 April 2013. https://www.cdc.gov/leprosy/transmission/.
5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 Guidelines for the diagnosis, treatment and prevention of leprosy. World Health Organization. Regional Office for South-East Asia. 2018. p. xiii. ISBN 978-92-9022-638-3.
6. ↑ Learning from leprosy: insight into the human innate immune response. Advances in Immunology. 105. 2010. pp. 1–24. doi:10.1016/S0065-2776(10)05001-7. ISBN 978-0-12-381302-2.
7. ↑ 7.0 7.1 Encyclopedia of pestilence, pandemics, and plagues. Westport, Conn.[u.a.]: Greenwood Press. 2008. p. 351. ISBN 978-0-313-34102-1. https://archive.org/details/encyclopediaofpe00jose_0.
8. ↑ CDC (26 January 2018). "World Leprosy Day". https://www.cdc.gov/features/world-leprosy-day/index.html.
9. ↑ "Global leprosy situation, 2012". Weekly Epidemiological Record 87 (34): 317–328. August 2012. PMID 22919737.
10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 "Leprosy now: epidemiology, progress, challenges, and research gaps". The Lancet. Infectious Diseases 11 (6): 464–470. June 2011. doi:10.1016/S1473-3099(11)70006-8. PMID 21616456.
11. ↑ Walsh F (31 March 2007). "The hidden suffering of India's lepers". BBC News. http://news.bbc.co.uk/2/hi/programmes/from_our_own_correspondent/6510503.stm.
12. ↑ Lyn TE (13 September 2006). "Ignorance breeds leper colonies in China". Independat News & Media. http://www.iol.co.za/index.php?set_id=1&click_id=117&art_id=qw1158139440409B243.
13. ↑ Japan repealed its "Leprosy Prevention Laws" in 1996, but former patients still reside in sanatoriums.
* "Koizumi apologises for leper colonies". BBC News. 25 May 2001. http://news.bbc.co.uk/2/hi/asia-pacific/1350630.stm.
* "Former Hansen's disease patients still struggling with prejudice". Japan Times. 7 June 2007. http://search.japantimes.co.jp/cgi-bin/nn20070607f2.html.
14. ↑ "Forgotten victims of the virus". Bangkok Post. 6 July 2020. https://www.bangkokpost.com/life/social-and-lifestyle/1946504/forgotten-victims-of-the-virus.
15. ↑ "Neglected Tropical Diseases". 6 June 2011. https://www.cdc.gov/globalhealth/ntd/diseases/index.html.
16. ↑ Leprosy and stigma in the South Pacific: a region-by-region history with first-person accounts. Jefferson, N.C.: McFarland. 2011. p. 17. ISBN 978-0-7864-6323-7. https://books.google.com/books?id=lZPvQTJ8SE0C&pg=PA17.
17. ↑ "Leprology". Merriam-Webster. https://www.merriam-webster.com/medical/leprology.
18. ↑ "Signs and Symptoms | Hansen's Disease (Leprosy) | CDC". 22 October 2018. https://www.cdc.gov/leprosy/symptoms/index.html.
19. ↑ "Pathogenesis and Pathology of Leprosy". 11 February 2016. https://internationaltextbookofleprosy.org/chapter/pathology.
20. ↑ 20.0 20.1 WHO Expert Committee on Leprosy – Eighth report. World Health Organization (WHO). 2012. pp. 11–12. ISBN 978-92-4-120968-7. http://www.searo.who.int/entity/global_leprosy_programme/publications/8th_expert_comm_2012.pdf. Retrieved 9 May 2018.
21. ↑ "Clinical aspects of leprosy". Clinics in Dermatology 33 (1): 26–37. 2015. doi:10.1016/j.clindermatol.2014.07.002. PMID 25432808.
22. ↑ Kulkarni GS (2008). Textbook of Orthopedics and Trauma (2nd ed.). Jaypee Brothers Publishers. p. 779. ISBN 978-81-8448-242-3.
23. ↑ "Q and A about leprosy". American Leprosy Missions. http://www.leprosy.org/leprosy-faqs. "Do fingers and toes fall off when someone gets leprosy? No. The bacillus attacks nerve endings and destroys the body's ability to feel pain and injury. Without feeling pain, people injure themselves on fire, thorns, rocks, and even hot coffee cups. Injuries become infected and result in tissue loss. Fingers and toes become shortened and deformed as the cartilage is absorbed into the body."
24. ↑ "Leprosy As a Complex Infection: Breakdown of the Th1 and Th2 Immune Paradigm in the Immunopathogenesis of the Disease". Frontiers in Immunology 8. 28 November 2017. doi:10.3389/fimmu.2017.01635. PMID 29234318.
25. ↑ 25.00 25.01 25.02 25.03 25.04 25.05 25.06 25.07 25.08 25.09 25.10 25.11 25.12 "Interventions for ulceration and other skin changes caused by nerve damage in leprosy". The Cochrane Database of Systematic Reviews 2019 (7). July 2019. doi:10.1002/14651858.CD012235.pub2. PMID 31425632.
26. ↑ 26.0 26.1 "New Leprosy Bacterium: Scientists Use Genetic Fingerprint To Nail 'Killing Organism'". ScienceDaily. 28 November 2008. https://www.sciencedaily.com/releases/2008/11/081124141047.htm.
27. ↑ Sherris Medical Microbiology (4th ed.). McGraw Hill. 2004. pp. 451–53. ISBN 978-0-8385-8529-0. OCLC 61405904. https://archive.org/details/sherrismedicalmi00ryan.
28. ↑ "Genomics Insights into the Biology and Evolution of Leprosy Bacilli". 11 February 2016. https://internationaltextbookofleprosy.org/chapter/genomic-insights-biology-and-evolution-leprosy-bacilli.
29. ↑ McMurray DN (1996). "Mycobacteria and Nocardia". Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 978-0-9631172-1-2. OCLC 33838234. https://www.ncbi.nlm.nih.gov/books/NBK7812/.
30. ↑ "Uncultivable bacteria: implications and recent trends towards identification". Indian Journal of Medical Microbiology 20 (4): 174–177. October 2002. doi:10.1016/S0255-0857(21)03184-4. PMID 17657065.
31. ↑ "WHO | Microbiology: culture in vitro". World Health Organization (WHO). https://www.who.int/lep/in_vitro/en/.
32. ↑ "The Armadillo Model for Leprosy". 11 February 2016. https://internationaltextbookofleprosy.org/chapter/armadillos.
33. ↑ Loughry WJ, Truman RW, McDonough CM, Tilak MK, Garnier S, et al. (2009) "Is leprosy spreading among nine-banded armadillos in the southeastern United States?" J Wildl Dis 45: 144–52.
34. ↑ "Leprosy in red squirrels in Scotland". The Veterinary Record 175 (11): 285–286. September 2014. doi:10.1136/vr.g5680. PMID 25234460.
35. ↑ Monot M, Honoré N, Garnier T, Araoz R, Coppee JY, et al. (2005). "On the origin of leprosy". Science 308: 1040–42.
36. ↑ 36.0 36.1 "On the age of leprosy". PLOS Neglected Tropical Diseases 8 (2). February 2014. doi:10.1371/journal.pntd.0002544. PMID 24551248.
37. ↑ "Red squirrels in the British Isles are infected with leprosy bacilli" , Dr. Andrej Benjak, Prof Anna Meredith and others. Science, 11 November 2016. [1]. Retrieved 11 November 2016.
38. ↑ 38.0 38.1 "Could squirrel fur trade have contributed to England's medieval leprosy outbreak?". https://www.sciencedaily.com/releases/2017/10/171025103109.htm.
39. ↑ "Leprosy in pre-Norman Suffolk, UK: biomolecular and geochemical analysis of the woman from Hoxne". Journal of Medical Microbiology 66 (11): 1640–1649. November 2017. doi:10.1099/jmm.0.000606. PMID 28984227.
40. ↑ 40.0 40.1 "Epidemiologic trends of leprosy for the 21st century". Clinics in Dermatology 34 (1): 24–31. January 2016. doi:10.1016/j.clindermatol.2015.11.001. PMID 26773620.
41. ↑ 41.0 41.1 "Anti-PGL-1 Positivity as a Risk Marker for the Development of Leprosy among Contacts of Leprosy Cases: Systematic Review and Meta-analysis". PLOS Neglected Tropical Diseases 10 (5). May 2016. doi:10.1371/journal.pntd.0004703. PMID 27192199.
42. ↑ "Genetic dissection of immunity in leprosy". Current Opinion in Immunology 17 (1): 44–48. February 2005. doi:10.1016/j.coi.2004.11.006. PMID 15653309.
43. ↑ "Human immunodeficiency virus and leprosy: an update". Dermatologic Clinics 29 (1): 125–128. January 2011. doi:10.1016/j.det.2010.08.016. PMID 21095536.
44. ↑ "Epidemiology of Leprosy". 11 February 2016. https://www.internationaltextbookofleprosy.org/chapter/epidemiology-leprosy.
45. ↑ "Mycobacterium leprae's evolution and environmental adaptation". Acta Tropica 197. September 2019. doi:10.1016/j.actatropica.2019.105041. PMID 31152726.
46. ↑ "Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment". Actas Dermo-Sifiliograficas 104 (7): 554–563. September 2013. doi:10.1016/j.adengl.2012.03.028. PMID 23870850.
47. ↑ "Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - Part 1". An Bras Dermatol 89 (2): 205–218. Mar–Apr 2014. doi:10.1590/abd1806-4841.20142450. PMID 24770495.
48. ↑ "Hansen's Disease (Leprosy) Transmission". 29 April 2013. https://www.cdc.gov/leprosy/transmission/.
49. ↑ "Treatment of leprosy". BMJ 328 (7454): 1447–1448. June 2004. doi:10.1136/bmj.328.7454.1447. PMID 15205269.
50. ↑ 50.0 50.1 "What Is Leprosy?"| from News-Medical.Net – Latest Medical News and Research from Around the World. Web. 20 November 2010. "What is Leprosy?". News-Medical.net. 18 November 2009. http://www.news-medical.net/health/What-is-Leprosy.aspx. .
51. ↑ Harris, Gardiner (27 April 2011). "Armadillos Can Transmit Leprosy to Humans, Federal Researchers Confirm" (in en-US). The New York Times. ISSN 0362-4331. https://www.nytimes.com/2011/04/28/health/28leprosy.html.
52. ↑ Guiden, Mary (29 June 2018). "New evidence that wild armadillos spread leprosy to humans" (in en-US). News from the College of Veterinary Medicine and Biomedical Sciences. https://cvmbs.source.colostate.edu/new-evidence-that-wild-armadillos-spread-leprosy-to-humans/.
53. ↑ "Probable zoonotic leprosy in the southern United States". The New England Journal of Medicine 364 (17): 1626–1633. April 2011. doi:10.1056/NEJMoa1010536. PMID 21524213.
54. ↑ "Hansen's Disease (Leprosy) Transmission". 29 April 2013. https://www.cdc.gov/leprosy/transmission/.
55. ↑ 55.0 55.1 "Genetic Susceptibility to Leprosy-From Classic Immune-Related Candidate Genes to Hypothesis-Free, Whole Genome Approaches". Frontiers in Immunology 9. 20 July 2018. doi:10.3389/fimmu.2018.01674. PMID 30079069.
56. ↑ Manson's tropical diseases (22nd ed.). [Edinburgh]: Saunders. 2009. p. 1056. ISBN 978-1-4160-4470-3. https://books.google.com/books?id=CF2INI0O6l0C&pg=PA1056.
57. ↑ 57.0 57.1 Buschman, Ellen; Skamene, Emil (June 2004). "Linkage of leprosy susceptibility to Parkinson's disease genes". International Journal of Leprosy and Other Mycobacterial Diseases 72 (2): 169–170. doi:10.1489/1544-581X(2004)072<0169:LOLSTP>2.0.CO;2. PMID 15301585. http://ijl.ilsl.br/detalhe_artigo.php?id=OTg=.
58. ↑ 58.0 58.1 58.2 58.3 58.4 "Leprosy: an overview of pathophysiology". Interdisciplinary Perspectives on Infectious Diseases 2012. 2012. doi:10.1155/2012/181089. PMID 22988457.
59. ↑ 59.0 59.1 59.2 59.3 59.4 Fróes Júnior, Luis Alberto Ribeiro; Trindade, Maria Ângela Bianconcini; Sotto, Mirian Nacagami (2022). "Immunology of leprosy". International Reviews of Immunology 41 (2): 72–83. doi:10.1080/08830185.2020.1851370. PMID 33241709.
60. ↑ 60.0 60.1 60.2 Fróes Júnior, Luis Alberto Ribeiro; Sotto, Mirian Nacagami; Trindade, Maria Ângela Bianconcini (2022). "Leprosy: clinical and immunopathological characteristics". Anais Brasileiros de Dermatologia 97 (3): 338–347. doi:10.1016/j.abd.2021.08.006. PMID 35379512.
61. ↑ 61.0 61.1 Fróes Júnior, Luis Alberto Ribeiro; Pagliari, Carla; Trindade, Maria Ângela Bianconcini; Sotto, Mirian Nacagami (2025). "B-cell subsets in leprosy lesions: unraveling the complex interplay". Anais Brasileiros de Dermatologia 100 (5). doi:10.1016/j.abd.2025.501184. PMID 40784052.
62. ↑ "International Textbook of Leprosy". September 2016. p. 3, Section 2.3. https://www.internationaltextbookofleprosy.org/sites/default/files/ITL_2_3 FINAL.pdf.
63. ↑ 63.0 63.1 U.S. Department of Health and Human Services, Health Resources and Services Administration. (n.d.). National Hansen's disease (leprosy) program. Retrieved from "National Hansen's Disease (Leprosy) Program". http://www.hrsa.gov/hansens/.
64. ↑ 64.0 64.1 "PCR-based techniques for leprosy diagnosis: from the laboratory to the clinic". PLOS Neglected Tropical Diseases 8 (4). April 2014. doi:10.1371/journal.pntd.0002655. PMID 24722358.
65. ↑ "Polymerase Chain Reaction (PCR) as a Potential Point of Care Laboratory Test for Leprosy Diagnosis-A Systematic Review". Tropical Medicine and Infectious Disease 3 (4): 107. October 2018. doi:10.3390/tropicalmed3040107. PMID 30275432.
66. ↑ Quilter, Emily E. V.; Butlin, Cynthia Ruth; Carrion, Carme; Ruiz-Postigo, Jose-Antonio (1 June 2024). "The WHO Skin NTD mobile application – a paradigm shift in leprosy diagnosis through Artificial Intelligence?". Leprosy Review 95 (2): 1–3. doi:10.47276/lr.95.2.2024030. ISSN 2162-8807. https://leprosyreview.org/article/95/2/20-24030. Retrieved 27 May 2024.
67. ↑ "Leprosy" (in en). https://www.who.int/news-room/fact-sheets/detail/leprosy.
68. ↑ "Pitfalls in the cytological classification of borderline leprosy in the Ridley-Jopling scale". Diagnostic Cytopathology 30 (6): 386–388. June 2004. doi:10.1002/dc.20012. PMID 15176024.
69. ↑ "Classification of leprosy according to immunity. A five-group system". International Journal of Leprosy and Other Mycobacterial Diseases 34 (3): 255–273. 1966. PMID 5950347.
70. ↑ Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. 2006. pp. 344–46. ISBN 978-0-7216-2921-6. https://archive.org/details/andrewsdiseasess00mdwi_659.
71. ↑ 71.0 71.1 "Leprosy: a review of laboratory and therapeutic aspects--part 2". Anais Brasileiros de Dermatologia 89 (3): 389–401. 2014. doi:10.1590/abd1806-4841.20142460. PMID 24937811.
72. ↑ "Clinical Diagnosis of Leprosy". 11 February 2016. https://internationaltextbookofleprosy.org/chapter/diagnosis-leprosy.
73. ↑ "Criteria for diagnosis of pure neural leprosy". Journal of Neurology 250 (7): 806–809. July 2003. doi:10.1007/s00415-003-1081-5. PMID 12883921.
74. ↑ "Primary neuritic leprosy: a reappraisal at a tertiary care hospital". Indian Journal of Leprosy 78 (3): 261–267. 2006. PMID 17120509.
75. ↑ "Three cases of pure neuritic (PN) leprosy at detection in which skin lesions became visible during their course". Nihon Hansenbyo Gakkai Zasshi = Japanese Journal of Leprosy 69 (2): 101–106. July 2000. doi:10.5025/hansen.69.101. PMID 10979277.
76. ↑ "Neuritic leprosy: further progression and significance". Acta Leprologica 9 (4): 187–194. 1995. PMID 8711979.
77. ↑ "Neuritic leprosy: epidemiology and therapeutic responsiveness". Leprosy Review 63 (3): 263–268. September 1992. doi:10.5935/0305-7518.19920031. PMID 1406021.
78. ↑ "Embrace a village - FAQ". 3 June 2021. https://www.embraceavillage.org/what-is-leprosy/.
79. ↑ "Advances and hurdles on the way toward a leprosy vaccine". Human Vaccines 7 (11): 1172–1183. November 2011. doi:10.4161/hv.7.11.16848. PMID 22048122.
80. ↑ "The role of BCG in prevention of leprosy: a meta-analysis". The Lancet. Infectious Diseases 6 (3): 162–170. March 2006. doi:10.1016/S1473-3099(06)70412-1. PMID 16500597.
81. ↑ "BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control". Expert Review of Vaccines 9 (2): 209–222. February 2010. doi:10.1586/ERV.09.161. PMID 20109030.
82. ↑ World Health Organization (June 2018). "BCG vaccine: WHO position paper, February 2018 - Recommendations". Vaccine 36 (24): 3408–3410. doi:10.1016/j.vaccine.2018.03.009. PMID 29609965.
83. ↑ "Leprosy post-exposure prophylaxis: innovation and precision public health". The Lancet. Global Health 9 (1): e8–e9. January 2021. doi:10.1016/S2214-109X(20)30512-X. PMID 33338461.
84. ↑ "BCG: a vaccine with multiple faces". Human Vaccines & Immunotherapeutics 16 (8): 1841–1850. August 2020. doi:10.1080/21645515.2019.1706930. PMID 31995448.
85. ↑ "Leprosy Vaccine". American Leprosy Missions. http://www.leprosy.org/leprosy-vaccine/.
86. ↑ "Trial set for world's first leprosy vaccine". The Guardian. 6 June 2014. https://www.theguardian.com/global-development/2014/jun/06/trial-world-first-leprosy-vaccine.
87. ↑ "China's Mars plans, leprosy vaccine and self-driving taxis". Nature 537 (7618): 12–13. September 2016. doi:10.1038/537012a. PMID 27582199. Bibcode: 2016Natur.537...12..
88. ↑ Clinical trial number NCT03302897 for "Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers" at ClinicalTrials.gov
89. ↑ "A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults". Vaccine 38 (7): 1700–1707. February 2020. doi:10.1016/j.vaccine.2019.12.050. PMID 31899025.
90. ↑ Dr. Heiser, V., An American Doctor's Odyssey. W. W. Norton & Company, 1936
91. ↑ Victor G. Heiser, "Leprosy in the Philippine Islands," Public Health Report, 24 (13 August 1909)
92. ↑ da Silva Santos, Jocimar; da Costa Alves, Franciely; José Dos Santos Júnior, Efraim; Soares Sobrinho, José Lamartine; de La Roca Soares, Mônica Felts (2 January 2023). "Evolution of pediatric pharmaceutical forms for treatment of Hansen's disease (leprosy)" (in en). Expert Opinion on Therapeutic Patents 33 (1): 1–15. doi:10.1080/13543776.2023.2178301. ISSN 1354-3776. PMID 36755421. https://www.tandfonline.com/doi/full/10.1080/13543776.2023.2178301.
93. ↑ George J (2020). "Metabolism and interactions of antileprosy drugs". Biochemical Pharmacology 177 (July). doi:10.1016/j.bcp.2020.113993. PMID 32339493.
94. ↑ "WHO: MDT and drug resistance". World Health Organization (WHO). https://www.who.int/lep/mdt/resistance/en/.
95. ↑ "Update on the epidemiology, diagnosis, and treatment of leprosy". Médecine et Maladies Infectieuses 45 (9): 383–393. September 2015. doi:10.1016/j.medmal.2015.09.002. PMID 26428602.
96. ↑ 96.0 96.1 96.2 96.3 "The impact of leprosy on the mental wellbeing of leprosy-affected persons and their family members - a systematic review". Global Mental Health 7. 2020. doi:10.1017/gmh.2020.3. PMID 32742673.
97. ↑ "A systematic review of multi-level stigma interventions: state of the science and future directions". BMC Medicine 17 (1). February 2019. doi:10.1186/s12916-018-1244-y. PMID 30770756.
98. ↑ "WHO | Leprosy: new data show steady decline in new cases". https://www.who.int/neglected_diseases/news/Leprosy-new-data-show-steady-decline-in-new-cases/en/.
99. ↑ 99.0 99.1 99.2 "WHO | Global leprosy update, 2015: time for action, accountability and inclusion". World Health Organization (WHO). https://www.who.int/lep/resources/who_wer9135/en/.
100. ↑ Maggie Veatch (21 February 2019). "Leprosy still lurks in United States, study says". https://www.cnn.com/2019/02/21/health/leprosy-cases-study/index.html.
101. ↑ "About ILEP". ILEP. http://www.ilep.org.uk/about-ilep/.
102. ↑ "Epidemiology of Leprosy". 11 February 2016. https://www.internationaltextbookofleprosy.org/chapter/epidemiology-leprosy.
103. ↑ 103.0 103.1 103.2 ((World Health Organization)) (1985). Epidemiology of leprosy in relation to control. Report of a WHO Study Group. World Health Organization technical report series. 716. World Health Organization. pp. 1–60. ISBN 978-92-4-120716-4. OCLC 12095109.
104. ↑ "Number of new leprosy cases". World Health Organization (WHO). 20 February 2026. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/number-of-new-leprosy-cases.
105. ↑ 105.0 105.1 Monot, Marc; Honoré, Nadine; Garnier, Thierry; Araoz, Romul; Coppée, Jean-Yves; Lacroix, Céline; Sow, Samba; Spencer, John S. et al. (2005). "On the origin of leprosy". Science 308 (5724): 1040–1042. doi:10.1126/science/1109759. PMID 15894530. https://hal-pasteur.archives-ouvertes.fr/pasteur-00204117/file/Monot_science.pdf. Retrieved 22 November 2022.
106. ↑ "On the origin of leprosy". Science 308 (5724): 1040–1042. May 2005. doi:10.1126/science/1109759. PMID 15894530. https://hal-pasteur.archives-ouvertes.fr/pasteur-00204117/file/Monot_science.pdf. Retrieved 22 November 2022.
107. ↑ "Ancient skeletal evidence for leprosy in India (2000 B.C.)". PLOS ONE 4 (5). May 2009. doi:10.1371/journal.pone.0005669. PMID 19479078. Bibcode: 2009PLoSO...4.5669R.
108. ↑ "Infection, disease, and biosocial processes at the end of the Indus Civilization". PLOS ONE 8 (12). December 2013. doi:10.1371/journal.pone.0084814. PMID 24358372. Bibcode: 2013PLoSO...884814R.
109. ↑ "Ancient skeletal evidence for leprosy in India (2000 B.C.)". PLOS ONE 4 (5). May 2009. doi:10.1371/journal.pone.0005669. PMID 19479078. Bibcode: 2009PLoSO...4.5669R.
110. ↑ "DNA of Jesus-Era Shrouded Man in Jerusalem Reveals Earliest Case of Leprosy". 16 December 2009. https://www.sciencedaily.com/releases/2009/12/091216103558.htm.
111. ↑ "Ancient genomes reveal a high diversity of Mycobacterium leprae in medieval Europe". PLOS Pathogens 14 (5). May 2018. doi:10.1371/journal.ppat.1006997. PMID 29746563.
112. ↑ "The Name 'Leprosy'". Etc: A Review of General Semantics. 12. Institute of General Semantics. 1954. pp. 37–47. http://www.jstor.org/stable/24234298. Retrieved 13 April 2022.
113. ↑ "Mycobacterium leprae: A historical study on the origins of leprosy and its social stigma". Infezioni in Medicina 29 (4): 623–632. 10 December 2021. doi:10.53854/liim-2904-18. PMID 35146374. PMC 8805473. https://www.infezmed.it/media/journal/Vol_29_4_2021_18.pdf.
114. ↑ Haubrich, William S. (2003). Medical Meanings: A Glossary of Word Origins. ACP Press. p. 133. ISBN 978-1-930513-49-5. https://books.google.com/books?id=NXmlIwkQBLAC&pg=PA133.
115. ↑ Wilkins, Michael; Evans, Craig A.; Bock, Darrell; Köstenberger, Andreas J. (1 October 2013). The Gospels and Acts. B&H. p. 194. ISBN 978-1-4336-8101-1. https://books.google.com/books?id=QPKsBAAAQBAJ&pg=PT194. Retrieved 15 July 2018.
116. ↑ "Skin Diseases in the Bible and the Talmud". Encyclopedia of Jewish Medical Ethics. Feldheim Publishers. 2003. p. 951. ISBN 978-1-58330-592-8. https://books.google.com/books?id=aaklGZAID08C&pg=PA951.
117. ↑ Adams, Francis (1678). The Seven Books of Paulus Aegineta: Translated from the Greek with Commentary Embracing a Complete View of the Knowledge Possessed by the Greeks, Romans and Arabians on all Subjects Connected with Medicine and Surgery. London: Sydenham Society.
118. ↑ "Oppdagelsen av leprabasillen" (in no). Tidsskrift for den Norske Laegeforening 122 (7): 708–709. March 2002. PMID 11998735.
119. ↑ Rotberg, Robert I. (2001). Population History and the Family: A Journal of Interdisciplinary History Reader. MIT Press. p. 132. ISBN 978-0-262-68130-8. https://books.google.com/books?id=OiQM-GIe69kC&pg=PA132.
120. ↑ Lopopolo, Maria (2025). "Pre-European contact leprosy in the Americas and its current persistence". Science 389 (6758). doi:10.1126/science.adu7144. PMID 40440428. Bibcode: 2025Sci...389u7144L.
121. ↑ "Leprosy in New Zealand". The Journal of the Polynesian Society 97 (2): 115–152. 1988. PMID 11617451. http://www.jps.auckland.ac.nz/document/Volume_97_1988/Volume_97,_No._2/Leprosy_in_New_Zealand,_by_J._Z._Montgomerie,_p_115-152?action=null. Retrieved 3 September 2019.
122. ↑ 122.0 122.1 122.2 Magazine, Smithsonian; Wong, Kathleen M.. "The Trailblazing Black Woman Chemist Who Discovered a Treatment for Leprosy". https://www.smithsonianmag.com/history/the-trailblazing-black-woman-chemist-who-discovered-a-treatment-for-leprosy-180979772/.
123. ↑ "Syphilis through history". Encyclopædia Britannica.
124. ↑ Andrew Baum (1997). Cambridge handbook of psychology, health and medicine. Cambridge, UK: Cambridge University Press. p. 521. ISBN 978-0-521-43686-1. https://books.google.com/books?id=zVh30FrAuDsC&pg=PA521.
125. ↑ "Experimental and clinical studies on rifampicin in treatment of leprosy". British Medical Journal 1 (5688): 89–92. January 1970. doi:10.1136/bmj.1.5688.89. PMID 4903972.
126. ↑ "Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy". Lancet 1 (8283): 1199–1202. May 1982. doi:10.1016/S0140-6736(82)92334-0. PMID 6122970.
127. ↑ "Treatment | Hansen's Disease (Leprosy)". Centers for Disease Control and Prevention. 22 October 2018. https://www.cdc.gov/leprosy/health-care-workers/treatment.html.
128. ↑ "Communicable Diseases Department, Leprosy FAQ". World Health Organization (WHO). 25 May 2006. http://www.searo.who.int/en/section10/section373_11716.htm.
129. ↑ Arch Dermato Syphilis 1898; 44:159–174
130. ↑ "Dr E W Price, the discoverer of podoconiosis". Journal of Medical Biography 30 (1): 2–5. February 2022. doi:10.1177/0967772019888406. PMID 31735101.
131. ↑ leprosy Novartis (accessed on 14 April 2021)
132. ↑ "WHO donated MDT". World Health Organization (WHO). https://www.who.int/lep/mdt/donation/en/.
133. ↑ "Leprosy – Hidden Disease?". Science Reporter 49 (3). March 2012. http://nopr.niscair.res.in/handle/123456789/13672. Retrieved 4 August 2019.
134. ↑ "The stigmatization of leprosy in India and its impact on future approaches to elimination and control". PLOS Neglected Tropical Diseases 2 (1). January 2008. doi:10.1371/journal.pntd.0000113. PMID 18235845.
135. ↑ "Leprosy in the Bible". Clinics in Dermatology 34 (1): 3–7. January 2016. doi:10.1016/j.clindermatol.2015.10.003. PMID 26773616.
136. ↑ [See: Orr, James, M.A., D.D. General Editor. "Entry for 'Leper; Leprosy'". "International Standard Bible Encyclopedia". 1915. Access-date=6 January 2017
137. ↑ "Is Tzaraat Leprosy?". 6 April 2022. https://www.chabad.org/library/article_cdo/aid/4714280/jewish/Is-Tzaraat-Leprosy.htm.
138. ↑ The Miracles of Jesus. Brill Archive. 1968. p. 464. https://books.google.com/books?id=n4geAAAAIAAJ&pg=PA464. Retrieved 21 May 2022.
139. ↑ "A Lesson from Leviticus: Leprosy". Man 22 (4): 598. December 1987. doi:10.2307/2803354.
140. ↑ 140.0 140.1 140.2 "People with leprosy (Hansen's disease) during the Middle Ages". Social Science Journal 38 (2): 315–21. 2001. doi:10.1016/S0362-3319(01)00116-1. http://his.library.nenu.edu.cn/upload/soft/haoli/114/372.pdf. Retrieved 25 June 2016.
141. ↑ "Recent Perspectives on Leprosy in Medieval Western Europe". History Compass 8 (5): 388–406. 2010. doi:10.1111/j.1478-0542.2009.00674.x.
142. ↑ "The Order of Saint Lazarus and the Crusades". The Catholic Historical Review 80 (3): 439–456. July 1994.
143. ↑ 143.0 143.1 143.2 143.3 143.4 "Medieval Leprosy Reconsidered". International Social Science Review 81 (1/2): 16–28. 2006.
144. ↑ Walking Corpses: Leprosy in Byzantium and the Medieval West. Cornell University Press. 19 April 2014. ISBN 978-0-8014-7076-9.
145. ↑ The Medieval world. London: Collins & Brown. 1990. ISBN 978-1-85585-081-1. https://archive.org/details/medievalworld0000unse.
146. ↑ The Mediaeval Hospitals of England. Methuen & Co.. 1909. pp. 36–37, 277–337. OCLC 4008302. https://archive.org/details/mediaevalhospita00clayuoft/mediaevalhospita00clayuoft/page/n3/mode/2up.
147. ↑ Medieval English medicine. New York: Barnes & Noble Books: Newton Abbot: David & Charles. 1974. ISBN 978-0-06-496016-8. https://archive.org/details/medievalenglishm0000rubi.
148. ↑ 148.0 148.1 148.2 "Medieval Leprosy". 24 April 2017. https://intriguing-history.com/medieval-leprosy/.
149. ↑ 149.0 149.1 "People with leprosy (Hansen's disease) during the Middle Ages". The Social Science Journal 38 (2): 315–21. 1 June 2001. doi:10.1016/S0362-3319(01)00116-1.
150. ↑ The Formation of a Persecuting Society. Oxford: Blackwell. 2007. ISBN 978-1-4051-2964-0.
151. ↑ von Zach, Franz Xaver (March 1798). "Einige Nachrichten von den Cagots in Frankreich" (in de). Allgemeine geographische Ephemeriden 1 (5): 509–524. https://zs.thulb.uni-jena.de/rsc/viewer/jportal_derivate_00200951/AGE_1798_Bd01_0509.tif.
152. ↑ Tuke, D. Hack (1880). "The Cagots". The Journal of the Anthropological Institute of Great Britain and Ireland (Wiley) 9: 376–385. doi:10.2307/2841703. https://zenodo.org/record/2119746.
153. ↑ British Medical Journal (11 May 1912). "Cagots". British Medical Journal 1 (2680): 1091–1092.
154. ↑ Alter A. (2010). Genetic susceptibility to leprosy. McGill University. ISBN 978-0-494-72613-6.
155. ↑ Svein Atle Skålevåg. "Daniel Cornelius Danielssen". Store norske leksikon. https://snl.no/Daniel_Cornelius_Danielssen.
156. ↑ Svein Atle Skålevåg (28 September 2014). "Carl Wilhelm Boeck". Store norske leksikon. https://snl.no/Carl_Wilhelm_Boeck.
157. ↑ 157.0 157.1 157.2 Gussow, Zachary (2021). Leprosy, Racism, And Public Health: Social Policy In Chronic Disease Control. Routledge. ISBN 978-0-3670-0292-3.
158. ↑ "Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives". Weekly Epidemiological Record 95 (36): 417–40. 4 September 2020.
159. ↑ "Hindu Marriage Act: Parliament passes law removing leprosy as ground for divorce". The Economic Times. 13 February 2019. https://economictimes.indiatimes.com/news/politics-and-nation/parliament-passes-law-removing-leprosy-as-ground-for-divorce/articleshow/67974143.cms?from=mdr.
160. ↑ Disease: The extraordinary stories behind history's deadliest killers. UK: Quercus Editions Ltd. 2013. pp. 26–27. ISBN 978-1-4351-5166-6.
161. ↑ 161.0 161.1 Bhukhan, Aashni; Dunn, Charles; Nathoo, Rajiv (2023). "Case Report of Leprosy in Central Florida, USA, 2022". Emerging Infectious Diseases 29 (8): 1698–1700. doi:10.3201/eid2908.220367. PMID 37486691.
162. ↑ admin (11 February 2016). "Stigma Related to Leprosy – A Scientific View". https://internationaltextbookofleprosy.org/chapter/stigma-quantitative.
163. ↑ "Explaining a complex disease process: talking to patients about Hansen's disease (leprosy) in Brazil". Medical Anthropology Quarterly 19 (3): 310–330. September 2005. doi:10.1525/maq.2005.19.3.310. PMID 16222964.
164. ↑ "Leprosy and Its Stigma Are Both Curable". https://www.mcgill.ca/oss/article/health-and-nutrition-history/leprosy-and-its-stigma-are-both-curable.
165. ↑ "Self-mortification and the stigma of leprosy in northern India". Medical Anthropology Quarterly 19 (2): 216–230. June 2005. doi:10.1525/maq.2005.19.2.216. PMID 15974328.
166. ↑ 166.0 166.1 166.2 "WHO | The Global Leprosy Strategy". http://www.who.int/lep/strategy/en/.
167. ↑ "The final push strategy to eliminate leprosy as a public health problem: questions and answers". 18 September 2003. https://www.who.int/publications/i/item/WHO-CDS-CPE-CEE-2003.37.
168. ↑ "WHO | Elimination of leprosy FAQ". http://www.who.int/lep/strategy/faqs/en/.
169. ↑ 169.0 169.1 "Leprosy elimination". World Health Organization (WHO). https://www.who.int/lep/en/.
170. ↑ "Communities of the afflicted: constituting leprosy through place in South India". Medical Anthropology 33 (1): 6–20. 2014. doi:10.1080/01459740.2012.714021. PMID 24383749. https://bura.brunel.ac.uk/handle/2438/10276. Retrieved 22 November 2022.
171. ↑ Hamilton, Bernard (2000). The leper king and his Heirs: Baldwin IV and the Crusader Kingdom of Jerusalem. Cambridge: Cambridge University Press. ISBN 978-0-521-64187-6.
172. ↑ Disease Selection: The Way Disease Changed the World. CABI. 2015. p. 8. ISBN 978-1-78064-682-4. https://books.google.com/books?id=jC8ZCwAAQBAJ&pg=PA8.
173. ↑ Bryant A (1995). Sekigahara 1600: The Final Struggle for Power (Campaign Series, 40). Osprey Publishing (UK). ISBN 978-1-85532-395-7. https://books.google.com/books?id=7i9nAAAAMAAJ. Retrieved 28 February 2010.
174. ↑ Ring, Barbra; Aubert, Elise; Winsnes, Hanna; Vogt, Johanne (1983). Aasen, Elisabeth. ed (in no). Fra gamle dage: memoarer, dagbøker, salmer og dikt av kvinner ca. 1660-1880. Universitetsforlaget. pp. 69–75. ISBN 82-00-06250-3. https://www.nb.no/items/URN:NBN:no-nb_digibok_2007062801008?page=69.
175. ↑ The Colony: The Harrowing True Story of the Exiles of Molokai. New York: Simon and Schuster. 2007. ISBN 978-0-7432-3301-9. https://books.google.com/books?id=rKUaLE6s1lgC.
176. ↑ 176.0 176.1 "A look at 6 contested historical events of Seychelles". Seychelles News Agency. http://www.seychellesnewsagency.com/articles/7354/A+look+at++contested+historical+events+of+Seychelles.
177. ↑ 177.0 177.1 "Seychelles: 14 Inspiring Women of Seychelles". Seychelles News Agency (Victoria). 9 March 2017. http://allafrica.com/stories/201703090796.html.
178. ↑ 178.0 178.1 "Nation Home". Seychelles Nation. 14 January 2016. http://www.nation.sc/article.html?id=248100.
179. ↑ "Diocesan committee prepares to commemorate Josephine Cafrine's 109th death anniversary". Seychelles Weekly. 8 January 2016. http://www.seychellesweekly.com/2016/January 4, 2016/soc1aa_commemorate_josephine_cafrine.html.
180. ↑ Cung giu Nguyên (1955). "Contemporary Vietnamese Writing". Books Abroad (University of Oklahoma) 29 (1): 19–25. doi:10.2307/40093803.
181. ↑ "5 Famous Spies Who Made Philippine History". Esquiremag.ph. 8 January 2018. https://www.esquiremag.ph/the-good-life/pursuits/5-famous-spies-that-made-philippine-history-a00184-20180108-lfrm.
182. ↑ Contreras, Volt (8 May 2006). "Ex-leper led bid for Culion town status". Philippine Daily Inquirer: p. A6. https://news.google.com/newspapers?id=klc1AAAAIBAJ&sjid=iiUMAAAAIBAJ&pg=2786,3009947.
183. ↑ "Dimple Kapadia: The Bollywood actress who has overcome leprosy". December 2018. https://www.leprosymission.in/dimple-kapadia-the-bollywood-actress-who-has-overcome-leprosy/.
184. ↑ Fernandez, Jean (2016). "Recognizing the Leper: Hindu Myth, British Medicine, and the Crisis of Realism in Rudyard Kipling's "The Mark of the Beast"". Victorian Review 41: 89–105. doi:10.1353/vcr.2016.0011. https://muse.jhu.edu/article/635693. Retrieved 21 February 2024.
185. ↑ "A Burnt-Out Case | novel by Greene". https://britannica.com/topic/A-Burnt-Out-Case.
186. ↑ Squint. https://www.upress.state.ms.us/Books/S/Squint. Retrieved 20 January 2024.
187. ↑ "Leprosy in wild armadillos". Leprosy Review 76 (3): 198–208. September 2005. doi:10.47276/lr.76.3.198. PMID 16248207.
188. ↑ Liang, Jiayu (16 October 2023). "Leprosy in Florida: medical experts monitoring unusual, new cases of Hansen's disease". https://epi.ufl.edu/2023/10/16/leprosy-in-florida-medical-experts-monitoring-unusual-new-cases-of-hansens-disease.
189. ↑ 189.0 189.1 189.2 Adams, L. B. (2021). "Susceptibility and resistance in leprosy: Studies in the mouse model". Immunological Reviews 301 (1): 157–174. doi:10.1111/imr.12960. PMID 33660297.
190. ↑ "The armadillo: a model for the neuropathy of leprosy and potentially other neurodegenerative diseases". Disease Models & Mechanisms 6 (1): 19–24. January 2013. doi:10.1242/dmm.010215. PMID 23223615.
191. ↑ "The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies to PGL-1". Indian Journal of Leprosy 64 (2): 137–151. April 1992. INIST:4390813. PMID 1607712.
192. ↑ 192.0 192.1 Truman, R. W.; Ebenezer, G. J.; Pena, M. T.; Sharma, R.; Balamayooran, G.; Gillingwater, T. H.; Scollard, D. M.; McArthur, J. C. et al. (2014). "The armadillo as a model for peripheral neuropathy in leprosy". ILAR Journal 54 (3): 304–314. doi:10.1093/ilar/ilt050. PMID 24615444.
193. ↑ Bittel, Jason (28 June 2016). "Humans Gave Leprosy to Armadillos. Now, They're Giving It Back". https://www.nationalgeographic.com/animals/article/Armadillos-leprosy-bacteria-amazon-brazil-nine-banded-animals#.
194. ↑ "Leprosy, ancient scourge of humans, found to assail wild chimpanzees". Science. 11 November 2020. https://www.science.org/content/article/leprosy-ancient-scourge-humans-found-assail-wild-chimpanzees.
195. ↑ "Leprosy in Red Squirrels in the UK". Veterinary Record 184 (13): 416. 30 March 2019. doi:10.1136/vr.l1385. PMID 30926706. https://www.researchgate.net/publication/332568227. Retrieved 25 May 2022.
196. ↑ Kennedy, Maev (25 October 2017). "Medieval love of squirrel fur may have helped spread leprosy, study reveals". Guardian. https://www.theguardian.com/science/2017/oct/25/medieval-love-of-squirrel-fur-may-have-helped-spread-leprosy-study-reveals.
197. ↑ "Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection". Cell 152 (1–2): 51–67. January 2013. doi:10.1016/j.cell.2012.12.014. PMID 23332746.
198. ↑ "Leprosy bacteria use 'biological alchemy'". BBC News. 17 January 2013. https://www.bbc.com/news/health-21056644.
199. ↑ "In vivo partial reprogramming by bacteria promotes adult liver organ growth without fibrosis and tumorigenesis". Cell Reports. Medicine 3 (11). November 2022. doi:10.1016/j.xcrm.2022.100820. PMID 36384103.
200. ↑ "Leprosy: Ancient disease able to regenerate organs". BBC News. 16 November 2022. https://www.bbc.com/news/health-63626239.

## Further reading

* Pam Fessler (2020). Carville's Cure: Leprosy, Stigma, and the Fight for Justice. Liveright. ISBN 978-1-63149-503-8.
* ﻿Guidelines for the diagnosis, treatment and prevention of leprosy﻿ (Report). October 2018. ISBN 978-92-9022-638-3. https://www.who.int/publications/i/item/9789290226383.

## External links

| Wikimedia Commons has media related to Leprosy.

|

Classification|

* ICD-11: 1B20
* ICD-10: A30
* ICD-9-CM: 030
* OMIM: 246300
* MeSH: D007918
* DiseasesDB: 8478

|

External resources|

* MedlinePlus: 001347
* eMedicine: med/1281 derm/223 neuro/187
* Scholia: Q36956

* v
* t
* e

Diseases of the skin and appendages by morphology

Growths|

| Epidermal|

* wart
* callus
* seborrheic keratosis
* acrochordon
* molluscum contagiosum
* actinic keratosis
* squamous-cell carcinoma
* basal-cell carcinoma
* Merkel-cell carcinoma
* nevus sebaceous
* trichoepithelioma

|

Pigmented|

* Freckles
* lentigo
* melasma
* nevus
* melanoma

Dermal and
subcutaneous|

* epidermal inclusion cyst
* hemangioma
* dermatofibroma (benign fibrous histiocytoma)
* keloid
* lipoma
* neurofibroma
* xanthoma
* Kaposi's sarcoma
* infantile digital fibromatosis
* granular cell tumor
* leiomyoma
* lymphangioma circumscriptum
* myxoid cyst

Rashes|

| With
epidermal
involvement|

| Eczematous|

* contact dermatitis
* atopic dermatitis
* seborrheic dermatitis
* stasis dermatitis
* lichen simplex chronicus
* Darier's disease
* glucagonoma syndrome
* langerhans cell histiocytosis
* lichen sclerosus
* pemphigus foliaceus
* Wiskott–Aldrich syndrome
* Zinc deficiency

|

Scaling|

* psoriasis
* tinea (corporis
* cruris
* pedis
* manuum
* faciei)
* pityriasis rosea
* secondary syphilis
* mycosis fungoides
* systemic lupus erythematosus
* pityriasis rubra pilaris
* parapsoriasis
* ichthyosis

Blistering|

* herpes simplex
* herpes zoster
* varicella
* bullous impetigo
* acute contact dermatitis
* pemphigus vulgaris
* bullous pemphigoid
* dermatitis herpetiformis
* porphyria cutanea tarda
* epidermolysis bullosa simplex

Papular|

* scabies
* insect bite reactions
* lichen planus
* miliaria
* keratosis pilaris
* lichen spinulosus
* transient acantholytic dermatosis
* lichen nitidus
* pityriasis lichenoides et varioliformis acuta

Pustular|

* acne vulgaris
* acne rosacea
* folliculitis
* impetigo
* candidiasis
* gonococcemia
* dermatophyte
* coccidioidomycosis
* subcorneal pustular dermatosis

Hypopigmented|

* tinea versicolor
* vitiligo
* pityriasis alba
* postinflammatory hyperpigmentation
* tuberous sclerosis
* idiopathic guttate hypomelanosis
* leprosy
* hypopigmented mycosis fungoides

Without
epidermal
involvement|

| Red|

| Blanchable
Erythema|

| Generalized|

* drug eruptions
* viral exanthems
* toxic erythema
* systemic lupus erythematosus

|

Localized|

* cellulitis
* abscess
* boil
* erythema nodosum
* carcinoid syndrome
* fixed drug eruption

Specialized|

* urticaria
* erythema (multiforme
* migrans
* gyratum repens
* annulare centrifugum
* ab igne)

Nonblanchable
Purpura|

| Macular|

* thrombocytopenic purpura
* actinic/solar purpura

|

Papular|

* disseminated intravascular coagulation
* vasculitis

Indurated|

* scleroderma/morphea
* granuloma annulare
* lichen sclerosis et atrophicus
* necrobiosis lipoidica

Miscellaneous
disorders|

| Ulcers|

|

Hair|

* telogen effluvium
* androgenic alopecia
* alopecia areata
* systemic lupus erythematosus
* tinea capitis
* loose anagen syndrome
* lichen planopilaris
* folliculitis decalvans
* acne keloidalis nuchae

Nail|

* onychomycosis
* psoriasis
* paronychia
* ingrown nail

Mucous
membrane|

* Aphthous stomatitis
* oral candidiasis
* lichen planus
* leukoplakia
* pemphigus vulgaris
* mucous membrane pemphigoid
* cicatricial pemphigoid
* herpesvirus
* coxsackievirus
* syphilis
* systemic histoplasmosis
* squamous-cell carcinoma

* v
* t
* e

Gram-positive bacterial infection: Actinobacteria (primarily A00–A79, 001–041, 080–109)

Actinomycineae|

| Actinomycetaceae|

* Actinomyces israelii
* Actinomycosis
* Cutaneous actinomycosis
* Tropheryma whipplei
* Whipple's disease
* Arcanobacterium haemolyticum
* Arcanobacterium haemolyticum infection
* Actinomyces gerencseriae

|

Propionibacteriaceae|

* Propionibacterium acnes

Corynebacterineae|

| Mycobacteriaceae|

| M. tuberculosis/
M. bovis|

* Tuberculosis: Ghon focus/Ghon's complex
* Pott disease
* brain
* Meningitis
* Rich focus
* Tuberculous lymphadenitis
* Tuberculous cervical lymphadenitis
* cutaneous
* Scrofuloderma
* Erythema induratum
* Lupus vulgaris
* Prosector's wart
* Tuberculosis cutis orificialis
* Tuberculous cellulitis
* Tuberculous gumma
* Lichen scrofulosorum
* Tuberculid
* Papulonecrotic tuberculid
* Primary inoculation tuberculosis
* Miliary
* Tuberculous pericarditis
* Urogenital tuberculosis
* Multi-drug-resistant tuberculosis
* Extensively drug-resistant tuberculosis

|

M. leprae|

* Leprosy: Tuberculoid leprosy
* Borderline tuberculoid leprosy
* Borderline leprosy
* Borderline lepromatous leprosy
* Lepromatous leprosy
* Histoid leprosy

Nontuberculous|

| R1:|

* M. kansasii
* M. marinum
* Aquarium granuloma

|

R2:|

* M. gordonae

R3:|

* M. avium complex/Mycobacterium avium/Mycobacterium intracellulare/MAP
* MAI infection
* M. ulcerans
* Buruli ulcer
* M. haemophilum

R4/RG:|

* M. fortuitum
* M. chelonae
* M. abscessus

Nocardiaceae|

* Nocardia asteroides/Nocardia brasiliensis/Nocardia farcinica
* Nocardiosis
* Rhodococcus equi

Corynebacteriaceae|

* Corynebacterium diphtheriae
* Diphtheria
* Corynebacterium minutissimum
* Erythrasma
* Corynebacterium jeikeium
* Group JK corynebacterium sepsis

Bifidobacteriaceae|

* Gardnerella vaginalis

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Leprosy. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Leprosy&oldid=4355576"
*[c.]: circa
*[r]: reign
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template